Aquatic Capital Management LLC Boosts Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Aquatic Capital Management LLC grew its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 13.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,100 shares of the company’s stock after buying an additional 7,100 shares during the quarter. Aquatic Capital Management LLC’s holdings in Twist Bioscience were worth $2,839,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC lifted its position in Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after purchasing an additional 104,420 shares during the period. Avanza Fonder AB bought a new position in Twist Bioscience during the fourth quarter valued at approximately $1,059,000. Principal Financial Group Inc. boosted its holdings in shares of Twist Bioscience by 67.5% in the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock worth $9,301,000 after purchasing an additional 82,953 shares during the period. Oddo BHF Asset Management Sas purchased a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $3,302,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Twist Bioscience by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after purchasing an additional 189,791 shares during the period.

Insider Transactions at Twist Bioscience

In related news, COO Patrick John Finn sold 2,058 shares of Twist Bioscience stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total value of $82,299.42. Following the sale, the chief operating officer now owns 265,460 shares of the company’s stock, valued at approximately $10,615,745.40. This trade represents a 0.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the sale, the insider now directly owns 112,221 shares in the company, valued at $5,538,106.35. This represents a 0.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,432 shares of company stock valued at $1,038,170 in the last 90 days. 3.01% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TWST shares. Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Barclays dropped their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Finally, Guggenheim set a $50.00 price objective on Twist Bioscience in a report on Friday, March 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and a consensus price target of $52.80.

Twist Bioscience Trading Down 0.5 %

Shares of NASDAQ TWST opened at $39.90 on Tuesday. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $39.51 and a two-hundred day simple moving average of $44.26. The firm has a market cap of $2.38 billion, a PE ratio of -11.80 and a beta of 2.34. Twist Bioscience Co. has a twelve month low of $30.32 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.75) EPS. Analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.